Daw S, Cole PD, Hoppe BS, Hodgson D, Beishuizen A, Garnier N, Buffardi S, Mascarin M, Lissat A, Mauz-Körholz C, Krajewski J, Akyol A, Crowe R, Anderson B, Xu Y, Drachtman RA, Kelly KM, Leblanc T, Harker-Murray P. Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults: A Nonrandomized Clinical Trial. JAMA Oncol. 2025 Mar 1;11(3):249-257. doi: 10.1001/jamaoncol.2024.5627. PMID: 39745739; PMCID: PMC11926625.
Study ID Citation
Abstract
In this nonrandomized clinical trial including 28 children, adolescents, and young adults with relapsed low-risk cHL, complete metabolic response rate per blinded independent central review any time before ISRT was 93%; the event-free and progression-free survival rates at 3 years were 87% and 95%, respectively. The safety profile was consistent with that of each agent used.